Related Experiment Video
Updated: Jan 13, 2026

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
Diagnostic Value of NO-Related Biomarkers (ADMA, NO, eNOS) in Stable COPD and Acute Exacerbation of COPD
Osman El Jundi1, Aysen Kutan Fenercioglu2, Pelin Uysal1,3
1Department of Chest Diseases, Faculty of Medicine, Istanbul Atlas University, Istanbul 34403, Turkey.
Abstract:
Background: Nitric oxide (NO)-related biomarkers, including asymmetric dimethylarginine (ADMA), nitric oxide (NO), and endothelial nitric oxide synthase (eNOS), may play a role in the pathophysiology and clinical progression of chronic obstructive pulmonary disease (COPD). This study aimed to investigate their diagnostic value in stable COPD and acute exacerbation. Methods: A total of 150 participants (76 females, 74 males; mean age 53.82 ± 7.06 years) were enrolled and equally distributed into control, stable COPD, and acute exacerbation groups (n = 50 each). Demographic, clinical, and laboratory parameters were compared across groups. Serum ADMA, NO, and eNOS levels were analyzed, and correlations with clinical findings were evaluated. ROC analysis was performed to determine the diagnostic performance of the biomarkers. Results: Serum ADMA levels were significantly higher in COPD patients, particularly in the acute exacerbation group (p < 0.05 for all comparisons). In contrast, NO and eNOS levels were significantly lower in COPD groups compared to controls (p < 0.05 for all comparisons). ADMA showed strong negative correlations with FEV1, FEV1/FVC, PaO2, and SaO2, whereas NO and eNOS showed positive correlations with the same parameters (all p < 0.01). For predicting acute exacerbation, an ADMA cut-off of 1.36 yielded high diagnostic accuracy (AUC = 0.983; sensitivity 86.0%; specificity 96.0%). eNOS also demonstrated predictive value (AUC = 0.823). For stable COPD, NO at a cut-off of 14.91 showed excellent diagnostic performance (AUC = 0.921). Conclusions: NO-related biomarkers, particularly ADMA and NO, may serve as reliable indicators for differentiating between stable COPD and acute exacerbation. Elevated ADMA and reduced NO and eNOS levels were closely associated with impaired lung function and oxygenation parameters. These findings suggest potential clinical utility of these biomarkers in COPD monitoring and management.
More Related Videos
08:44Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
Published on: February 2, 2024
04:53Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
Published on: October 18, 2024
Related Concept Videos
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-I: Introduction
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
COPD: Management Using Bronchodilators and Corticosteroids
Acute Coronary Syndrome III: Diagnostic Studies